Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) - Conditions are Likely to Rise in the Near Future Due to the Consequences of COVID-19 - ResearchAndMarkets.com

The "Pharmaceutical Treatments for Mental Health Disorders: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.

Companies Mentioned

• Abbvie
• Acadia Pharmaceuticals Inc.
• Adamis Pharmaceuticals Corp.
• Alkermes Plc
• Astrazeneca Plc
• Bioxcel Therapeutics Inc.
• Boehringer Ingelheim International Gmbh
• Eli Lilly & Co.
• Glaxosmithkline Plc
• H Lundbeck A/S
• Intervexion Therapeutics
• Intra-Cellular Therapies Inc.
• Ironshore Pharmaceuticals
• Johnson & Johnson
• Kempharm Inc.
• Minerva Neurosciences Inc.
• Neos Therapeutics Inc.
• NLS Pharmaceutical Ag
• Noven Pharmaceuticals Inc.
• Orexo Ab
• Otsuka Holdings Co. Ltd.
• Pear Therapeutics
• Pfizer Inc.
• Sage Therapeutics
• Shionogi & Co. Ltd.
• Specialty Pharma And Biotechs
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceuticals Co. Ltd.
• Tonix Pharmaceuticals Holdings Corp.
• Tris Pharma Inc.

Report Includes:

• 46 data tables and 12 additional tables
• An overview of the global markets for pharmaceutical treatments for mental health disorders
• Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
• Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
• Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COVID-19 pandemic, social distancing and social isolation on the mental health conditions
• A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
• Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
• Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
• Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
• Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies

Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COVID-19 pandemic, social distancing and social isolation.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Depression and Anxiety

• Market Landscape
• Segmentation by Drug Class
• Segmentation by Company
• Prevalence of Disorders
• Diagnosis
• Current Treatments
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
• Tricyclic Antidepressants (TCAs)
• Monoamine Oxidase Inhibitors (MAOIs)
• Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs)
• Benzodiazepines
• Recent Drug Developments
• Drug/Company
• Late-Stage Drug Failures/Withdrawals
• Drugs in Clinical Development to Treat Depression
• Phase 3 Drugs in Development to Treat Depression
• Phase 2 Drugs in Development to Treat Depression
• Drugs in Clinical Development to Treat Anxiety
• Phase 3 Drugs in Development to Treat Anxiety
• Phase 2 Drugs in Development to Treat Anxiety
• Alternative Approaches
• Digital Therapeutics
• M&A Activity
• Future Opportunities

Chapter 4 Attention Deficit Hyperactivity Disorder

• Market Landscape
• Segmentation by Geography
• Segmentation by Drug Class
• Segmentation by Company
• Prevalence
• Diagnosis
• Current Treatments
• Recent Drug Developments
• Drugs/Companies
• Late-Stage Drug Failures/Withdrawals
• Drugs in Clinical Development to Treat ADHD
• Phase 3 Drugs in Development to Treat ADHD
• Phase 2 Drugs in Development to Treat ADHD
• Alternative Approaches
• Digital Therapeutics
• M&A Activity
• Future Opportunities

Chapter 5 Schizophrenia

• Market Landscape
• Segmentation by Geography
• Segmentation by Drug Class
• Segmentation by Company
• Prevalence
• Diagnosis
• Current Treatments
• Recent Drug Developments
• Drugs/Companies
• Late-Stage Drug Failures/Withdrawals
• Drugs in Clinical Development to Treat Schizophrenia
• Phase 3 Drugs in Development to Treat Schizophrenia
• Phase 2 Drugs in Development to Treat Schizophrenia
• Alternative Approaches
• Digital Therapeutics
• M&A Activity
• Future Opportunities

Chapter 6 Substance Use Disorders

• Market Landscape
• Segmentation by Geography
• Segmentation by Drug Class
• Segmentation by Company
• Prevalence
• Diagnosis
• Current Treatments
• Opioid Use Disorders
• Alcohol Use Disorders
• Nicotine Use Disorders
• Recent Drug Developments
• Drugs in Clinical Development to Substance Abuse Disorder
• Phase 3 Drugs in Development to Treat Substance Use Disorders
• Phase 2 Drugs in Development to Treat Substance Use Disorder
• Alternative Approaches
• Digital Therapeutics
• M&A Activity
• Future Opportunities

Chapter 7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/oqajq2

View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005783/en/